140 related articles for article (PubMed ID: 16186303)
1. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider.
Misbin RI
Diabetes Care; 2005 Oct; 28(10):2573-6. PubMed ID: 16186303
[No Abstract] [Full Text] [Related]
2. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
3. Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
Isaacsohn JL; Troendle AJ; Orloff DG
Am J Cardiol; 2004 Jun; 93(11A):49C-52C. PubMed ID: 15178516
[No Abstract] [Full Text] [Related]
4. Cardiovascular safety and diabetes drug development.
Drucker DJ; Goldfine AB
Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
[No Abstract] [Full Text] [Related]
5. A voyage of discovery.
Gebel E
Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
[No Abstract] [Full Text] [Related]
6. Class of once-weekly diabetes drugs poised for approval.
Waters H
Nat Med; 2011 Dec; 17(12):1528. PubMed ID: 22146435
[No Abstract] [Full Text] [Related]
7. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
Kuehn BM
JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
[No Abstract] [Full Text] [Related]
8. Coming Soon to a Pharmacy Near You.
Dubois W
Diabetes Self Manag; 2016; 33(3):88-91. PubMed ID: 27290782
[TBL] [Abstract][Full Text] [Related]
9. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.
Joffe HV; Parks MH; Temple R
Rev Endocr Metab Disord; 2010 Mar; 11(1):21-30. PubMed ID: 20195772
[TBL] [Abstract][Full Text] [Related]
10. New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
Hussar DA; Kaczinski J
J Am Pharm Assoc (2003); 2010; 50(3):436-9. PubMed ID: 20452924
[No Abstract] [Full Text] [Related]
11. FDA drug-review, surveillance processes under scrutiny.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
[No Abstract] [Full Text] [Related]
12. Rethinking the appraisal and approval of drugs for type 2 diabetes.
Naci H; Lehman R; Wouters OJ; Goldacre B; Yudkin JS
BMJ; 2015 Oct; 351():h5260. PubMed ID: 26452524
[No Abstract] [Full Text] [Related]
13. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F; Stough WG; Lipicky RJ; Tamargo J; Bakris GL; Borer JS; Alonso García Mde L; Hadjadj S; Koenig W; Kupfer S; McCullough PA; Mosenzon O; Pocock S; Scheen AJ; Sourij H; Van der Schueren B; Stahre C; White WB; Calvo G
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):200-5. PubMed ID: 27418973
[TBL] [Abstract][Full Text] [Related]
14. Oncology drug development: United States Food and Drug Administration perspective.
Hirschfeld S; Pazdur R
Crit Rev Oncol Hematol; 2002 May; 42(2):137-43. PubMed ID: 12007971
[TBL] [Abstract][Full Text] [Related]
15. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor.
Jones D
Nat Rev Drug Discov; 2011 Aug; 10(9):645-6. PubMed ID: 21878967
[No Abstract] [Full Text] [Related]
16. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation.
DeLoughery EP; Prasad V
Ann Oncol; 2018 Mar; 29(3):527-529. PubMed ID: 29346605
[No Abstract] [Full Text] [Related]
17. FDA approach to the regulation of drugs for diabetes.
Fleming A
Am Heart J; 1999 Nov; 138(5 Pt 1):S338-45. PubMed ID: 10539795
[No Abstract] [Full Text] [Related]
18. Diabetes drugs: clinical trial.
Prout TE; Knatterud GL; Meinert CG
Science; 1979 Apr; 204(4391):362-3. PubMed ID: 375390
[No Abstract] [Full Text] [Related]
19. Basing approval of drugs for type 2 diabetes on real world outcomes.
McGovern A; Hinchliffe R; Munro N; de Lusignan S
BMJ; 2015 Nov; 351():h5829. PubMed ID: 26530057
[No Abstract] [Full Text] [Related]
20. Novo sets sights on obesity market with diabetes drug.
Sheridan C
Nat Biotechnol; 2014 Nov; 32(11):1071-2. PubMed ID: 25380424
[No Abstract] [Full Text] [Related]
[Next] [New Search]
